Schwarz To Push For Damages In Univasc Patent Suit Vs. Teva

Law360, New York (September 14, 2004, 12:00 AM EDT) -- German drug maker Schwarz Pharma will continue to seek damages from Israel's Teva in a patent dispute over Schwarz's hypertension drug Univasc, even though Teva agreed to pull its supply of its generic version of the drug pending the outcome of litigation between the two companies.

Schwarz said in a statement that there had been no settlement in its lawsuit against Teva, which alleges infringement of its patents by the Israeli company, and that it was ready to supply the U.S. market with its drug....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.